Updated survival, response and safety data in a phase 1 dose-finding study (CA209-004) of concurrent nivolumab (NIVO) and ipilimumab (IPI) in advanced melanoma

被引：0

作者：

Sznol, Mario ^{[1
,2
]}

Callahan, Margaret K. ^{[3
]}

Kluger, Harriet ^{[1
,2
]}

Postow, Michael A. ^{[3
,4
]}

Gordan, RuthAnn ^{[3
]}

Segal, Neil H. ^{[3
]}

Rizvi, Naiyer A. ^{[3
]}

Lesokhin, Alexander ^{[3
]}

Atkins, Michael B. ^{[5
]}

Kirkwood, John M. ^{[6
]}

Burke, Matthew M. ^{[1
,2
]}

Ralabate, Amanda ^{[1
,2
]}

Rivera, Angel ^{[1
,2
]}

Kronenberg, Stephanie A. ^{[3
]}

Agunwamba, Blessing ^{[3
]}

Ruisi, Mary ^{[7
]}

Horak, Christine ^{[8
]}

Jiang, Joel ^{[7
]}

Wolchok, Jedd ^{[3
]}

机构：

[1] Yale Univ, Sch Med, New Haven, CT USA

[2] Yale New Haven Med Ctr, Smilow Canc Ctr, New Haven, CT USA

[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[4] Weill Cornell Med Coll, New York, NY USA

[5] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA

[6] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA

[7] Bristol Myers Squibb, Princeton, NJ USA

[8] Bristol Myers Squibb, Lawrenceville, NJ USA

来源：

JOURNAL OF TRANSLATIONAL MEDICINE | 2016年 / 14卷

关键词：

D O I：

暂无

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

引用

页数：2

共 50 条

[1] Long-term follow-up of CA209-004: A phase I dose-escalation study of combined nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma.
Atkins, Michael B.
Kirkwood, John M.
Wolchok, Jedd D.
Callahan, Margaret K.
Kluger, Harriet M.
Postow, Michael A.
Segal, Neil Howard
Lesokhin, Alexander M.
Balogh, Agnes
Re, Sandra
Sznol, Mario
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[2] Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study
Callahan, Margaret K.
Kluger, Harriet
Postow, Michael A.
Segal, Neil H.
Lesokhin, Alexander
Atkins, Michael B.
Kirkwood, John M.
Krishnan, Suba
Bhore, Rafia
Horak, Christine
Wolchok, Jedd D.
Sznol, Mario
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04) : 391 - +
[3] SAFETY DATA FROM AN EXPANDED ACCESS PROGRAM (EAP) OF NIVOLUMAB (NIVO) IN COMBINATION WITH IPILIMUMAB (IPI) IN PATIENTS WITH ADVANCED MELANOMA (MEL)
Chapman, Paul B.
Sznol, Mario
Lao, Christopher D.
Gonzalez, Rene
Daniels, Gregory A.
Thompson, John A.
Kudchadkar, Ragini R.
Sharfman, William H.
Atkins, Michael B.
Pavlick, Anna C.
Infante, Jeffrey R.
Kim, Kevin B.
Weber, Jeffrey S.
Nair, Suresh
Cowey, Lance
Lipson, Evan J.
Lee, Sue
Avila, Alexandre
Hodi, Stephen
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 119 - 119
[4] Safety data from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL).
Chapman, Paul B.
Sznol, Mario
Lao, Christopher
Gonzalez, Rene
Daniels, Gregory A.
Thompson, John A.
Kudchadkar, Ragini Reiney
Sharfman, William Howard
Atkins, Michael B.
Pavlick, Anna C.
Infante, Jeffrey R.
Kim, Kevin
Weber, Jeffrey S.
Patel, Sapna Pradyuman
Nair, Suresh
Cowey, C. Lance
Lipson, Evan J.
Lee, Sue
Avila, Alexandre
Hodi, F. Stephen
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[5] Pooled 3-year overall survival data from phase II and phase III trials of nivolumab (NIVO) combined with ipilimumab (IPI) in advanced melanoma
Postow, Michael
Larkin, James
Wolchok, Jedd D.
Chiarion-Sileni, Vanna
Hodi, F. Stephen
Rutkowski, Piotr
Grob, Jean-Jacques
Grossmann, Kenneth
Schadendorf, Dirk
Chesney, Jason
Smylie, Michael
Hill, Andrew
Robert, Caroline
Pavlick, Anna C.
Haanen, John
McArthur, Grant A.
McDermott, David
Demelo, Sheena
Bhore, Rafia
Gonzalez, Rene
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
[6] CLINICAL RESPONSE, PROGRESSION-FREE SURVIVAL (PFS) AND SAFETY IN PATIENTS (PTS) WITH ADVANCED MELANOMA (MEL) RECEIVING NIVOLUMAB (NIVO) COMBINED WITH IPILIMUMAB (IPI) VERSUS IPI MONOTHERAPY IN CHECKMATE 069 STUDY
Hodi, F. Stephen
Postow, Michael A.
Chesney, Jason
Pavlik, Anna C.
Robert, Caroline
Grossman, Kenneth
McDermott, David
Linette, Gerald
Meyer, Nicolas
Giguere, Jeffrey K.
Agarwala, Sanjiv S.
Shaheen, Montaser
Ernstoff, Marc S.
Minor, David
Salama, April K.
Taylor, Matthew
Ott, Patrick A.
Horak, Christine
Gagnier, Paul
Wolchok, Jedd D.
Asia-Pacific Journal of Clinical Oncology, 2015, 11 : 109 - 109
[7] SURVIVAL, RESPONSE DURATION, AND ACTIVITY BY BRAF MUTATION (MT) STATUS OF NIVOLUMAB (NIVO, ANTI-PROGRAMMED DEATH-1) AND IPILIMUMAB (IPI) CONCURRENT THERAPY IN ADVANCED MELANOMA (MEL)
Sznol, Mario
Kluger, Harriet
Callahan, Margaret K.
Postow, Michael A.
Gordon, RuthAnn
Seal, Neil H.
Rizvi, Naiyer A.
Lesokhin, Alexander M.
Atkins, Michael B.
Kirkwood, John M.
Burke, Matthew M.
Ralabate, Amanda
Rivera, Angel
Kronenberg, Stephanie A.
Agunwamba, Blessing U.
Feely, William
Quan, Hong
Krishnan, Suba
Gupta, Ashok
Wolchok, Jedd D.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 188 - 188
[8] Phase 2 study to evaluate efficacy and safety of combination therapy with nivolumab (NIVO) and ipilimumab(IPI) in patients with previously untreated melanoma
Kiyohara, Y.
Takenouchi, T.
Uhara, H.
Koga, H.
Uchi, H.
Yamazaki, N.
ANNALS OF ONCOLOGY, 2017, 28
[9] Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study.
Hodi, F. Stephen
Postow, Michael Andrew
Chesney, Jason Alan
Pavlick, Anna C.
Robert, Caroline
Grossmann, Kenneth F.
McDermott, David F.
Linette, Gerald P.
Meyer, Nicolas
Giguere, Jeffrey K.
Agarwala, Sanjiv S.
Shaheen, Montaser F.
Ernstoff, Marc S.
Minor, David R.
Salama, April
Taylor, Matthew Hiram
Ott, Patrick Alexander
Horak, Christine E.
Gagnier, Paul
Wolchok, Jedd D.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[10] Updated results of phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with divergent histologies (RCCdh)
McGregor, B. A.
Paul, M.
Xie, W.
Xu, W.
Bilen, M. A.
Braun, D. A.
Berg, S.
Zhang, T.
McKay, R. R.
McDermott, D. F.
Hammers, H.
Choueiri, T. K.
ANNALS OF ONCOLOGY, 2024, 35 : S1020 - S1020

← 1 2 3 4 5 →